NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
Clinical Trials
36 trialsNCT04205812 2026-03-31
POD1UM-304
Incyte Corporation
Phase 3 Active not recruiting
NCT03631199 2026-02-25
CANOPY-1
Novartis
Phase 3 Terminated
NCT03734029 2025-10-06
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Daiichi Sankyo
Phase 3 Active not recruiting
NCT05014815 2025-09-16
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
BeiGene
Phase 2 Completed
NCT02734290 2025-03-10
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Providence Health & Services
Phase 1/2 Active not recruiting
NCT03601897 2024-12-27
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1/2 Terminated
NCT03430843 2024-10-26
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT01953926 2024-03-12
SUMMIT
Puma Biotechnology, Inc.
Phase 2 Terminated
NCT02954055 2024-02-26
METEORA-II
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT00993655 2023-08-28
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT02264990 2021-02-26
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
AbbVie
Phase 3 Completed
NCT03887442 2021-01-07
EXTAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 2 Terminated
NCT02280252 2020-11-23
Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
NYU Langone Health
Phase 2 Completed
NCT02124707 2020-08-12
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02322281 2019-08-14
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc.
Phase 3 Terminated
NCT00876395 2018-12-19
BOLERO-1
Novartis
Phase 3 Completed
NCT02560038 2018-11-28
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01852292 2018-07-24
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
Novartis
Phase 2 Terminated
NCT01006252 2018-07-17
SUMMIT-1
Eli Lilly and Company
Phase 3 Terminated
NCT01009515 2017-10-18
Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT01774851 2017-06-22
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Merrimack Pharmaceuticals
Phase 2 Terminated
NCT01108055 2017-06-09
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Stanford University
Phase 2 Completed
NCT00350025 2017-03-31
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT01572727 2017-03-09
BELLE-4
Novartis
Phase 2/3 Completed
NCT01209195 2016-09-08
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Merrimack Pharmaceuticals
Phase 1 Completed
NCT01447706 2016-05-12
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Merrimack Pharmaceuticals
Phase 2 Completed
NCT00900627 2016-01-20
THYME
AstraZeneca
Phase 1/2 Completed
NCT00426556 2015-12-28
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
Novartis
Phase 1 Completed
NCT01011075 2015-07-03
6137p
New Mexico Cancer Research Alliance
Phase 2 Completed
NCT01579578 2014-09-12
Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer
AstraZeneca
Phase 2 Terminated
NCT00476827 2013-07-17
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Duke University
Phase 2 Terminated
NCT00100789 2012-10-01
S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00048893 2012-04-13
Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated